The Oncologic Safety of Sentinel Lymph Node Biopsy in Patients with Node-Positive Breast Cancer with Complete Response to Neoadjuvant Chemotherapy: A Single-Center Experience.

Autor: Tercan IC; Department of General Surgery, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey., Zengel B; Department of General Surgery, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey., Ozdemir O; Department of Medical Oncology, Izmir Bozyaka Health Practice and Research Center, Izmir, Turkey., Cavdar D; Department of Pathology, Izmir Bozyaka Health Practice and Research Center, Izmir, Turkey., Tasli F; Department of Pathology, Izmir Bozyaka Health Practice and Research Center, Izmir, Turkey., Adibelli ZH; Department of Radiology, Izmir Bozyaka Health Practice and Research Center, Izmir, Turkey., Karatas M; Department of General Surgery, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey., Simsek C; Department of General Surgery, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey., Durusoy IR; Department of Public Health, Ege University, Medical Faculty, Izmir, Turkey., Uslu A; Department of General Surgery, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey.
Jazyk: angličtina
Zdroj: The breast journal [Breast J] 2023 Jan 04; Vol. 2023, pp. 4549033. Date of Electronic Publication: 2023 Jan 04 (Print Publication: 2023).
DOI: 10.1155/2023/4549033
Abstrakt: Objective: To evaluate the efficiency and safety of sentinel lymph node biopsy (SLNB) in patients with breast cancer with complete response to neoadjuvant chemotherapy (NAC).
Methods: Ninety-two consecutive (T1-4 and N1-2) patients with breast cancer who had pathologic and/or clinical and radiologic axillary lymph node involvement were included. All patients received NAC. Patients with a clinical and radiologic complete response in the axilla after NAC underwent SLNB. Pathologic complete response (ypCR) was defined as the absence of residual invasive and in situ cancer, and near-complete response (ypNCR) represented in situ and/or ≤ 1 mm residual tumor in the breast and/or presence of malignant cell clusters (≤0.2 mm) and/or micrometastases (≤2.0 mm) in the axillary lymph nodes (ALN) (ypTis/T1mi, ypN0i+/pN1mi).
Results: The mean age of the 92 patients was 49.6 ± 10.3 years and the mean follow-up was 34.0 ± 17.8 months. With respect to breast tumors, 23 (25.0%) patients had complete and 14 (15.2%) had a near-complete response to NAC. Complete response in ALN was obtained in 39 (42.4%) patients and near-complete in six (6.5%) patients. The overall survival of the 33 patients who achieved ypCR and ypNCR was 100% and the remaining 59 patients with partial or no response to NAC was 83.1% at a mean follow-up of 34 months ( p =0.063).
Conclusions: In this study, no event developed in cases with ypCR and ypNCR in the breast and axilla. The persistence of the same results in long-termfollow-ups may enable the use of ypNCR as a positive prognostic marker in addition to ypCR.
Competing Interests: The authors declare that they have no conflicts of interest.
(Copyright © 2023 Ismail Can Tercan et al.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje